Allied Market Research
Loading...
0
New
New

Novel Vaccine Delivery Systems Market by Delivery Mode (Intradermal, Subcutaneous, Intramuscular, and Other), Device (Syringe, Needle-Free Injection System, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030.

A11784
Pages: 208
Jun 2021 | 258 Views
   
Author(s) : Sushant Terdale , Onkar Sumant
Tables: 99
Charts: 23
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Novel Vaccine Delivery Systems Market

Request Now !

Novel Vaccine Delivery Systems Market Overview:

The global novel vaccine delivery systems market size was valued at $5,030 million in 2020 and is projected to reach $14,437 million by 2030 registering a CAGR of 10.8% from 2021 to 2030.

Vaccines, often known as immunizations, are injections that induce the body to generate antibodies or immunity against a disease. Vaccinations are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases. A vaccine generally consists of a disease-causing germ-like agent made from weakened or killed microorganisms, their toxins, or one of their surface proteins. The agent causes the body's immune system to recognize and destroy the agent as a threat. Novel vaccine delivery includes formulations, technologies, methods, and systems to transfer an active pharmaceutical ingredient in the body, as desired, in order to safely accomplish its therapeutic effect. 

Novel-Vaccine-Delivery-System-Market-2021-2030

Get more information on this report : Request Sample Pages

The growing immunization programs for various diseases such as polio, smallpox, COVID, and hepatitis among others, and their increasing coverage is the key factor that drives the growth of the global novel vaccine delivery system market. In addition, increasing government support for healthcare infrastructure improvements and robust R&D initiatives to produce vaccine with enhanced therapeutic potential and reduced side effects further boost the growth of the market. Moreover, investment of government for immunization programs and development of novel vaccines using various novel approaches further drive the market growth. High cost and unaffordability of safety syringes, as well as the availability of other drug administration methods may hamper the growth of the novel vaccine delivery system market. In contrast, rise in need for safety syringes in emerging economies and FDA approval for the COVID-19 vaccine created lucrative opportunities for the novel vaccine delivery system.

The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including novel vaccine delivery products such as syringe, needle free injection system. Medical disposables such as syringes and needles are a key to corona vaccine delivery, the pandemic is expected to have a positive impact on growth of the smart syringe market in the coming months. In addition, several contracts and tenders are announced by governments for manufacturing and providing syringes on a nationwide scale. For instance, in August 2020, Hindustan Syringes & Medical Devices Ltd. (HMD), confirmed that it has received an order of 140 million auto disable syringes for COVID-19 from the United Nations Children's Fund (UNICEF). Similarly, in July 2020, Retractable Technologies Inc. entered into Technology Investment Agreement (TIA) of $53.6 million with the U.S. government for expanding its domestic production of needles and syringes.

Novel Vaccine Delivery Systems Market Segmentation  

The global novel vaccine delivery systems market is segmented into delivery mode, device and region. On the basis of delivery mode, the market is categorized into intradermal, subcutaneous, intramuscular, and other. By device, it is classified into syringe, needle-free injection system, and others. Syringe again classified into conventional syringe and smart syringe. Smart syringe again segmented into active safety syringes, passive safety syringes, and auto disable syringes. Needle-free injection system again classified into spring-based injector systems, gas propelled/air forced injector system, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Based on delivery mode, the market is segmented into intradermal, subcutaneous, intramuscular, and other. The intramuscular segment dominates the global market in 2020 and is anticipated to continue this trend during the forecast period. The factor which drives the growth of this segment includes, intramuscular vaccine delivery mode are widely adopted as they deliver medications deep into the muscle tissues, which absorbs the medication quickly.

Novel Vaccine Delivery Systems Market
By Delivery Mode

Your browser does not support the canvas element.

Intramuscular segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

On the basis of device, the market is segmented into syringe, needle-free injection system, and others. Needle-free injection system again classified into spring-based injector systems, gas propelled/air forced injector system, and others. Syringe again classified into conventional syringe and smart syringe. Smart syringe again segmented into active safety syringes, passive safety syringes, and auto disable syringes.

The syringe segment is expected to account for the largest revenue during forecast period, owing to cost effectiveness of syringes and they are used in routine immunization and mass vaccination programs.

Novel Vaccine Delivery Systems Market
By Device

Your browser does not support the canvas element.

Syringe segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of the Asia-Pacific Novel Vaccine Delivery Systems Market  

Asia-Pacific is expected to exhibit the fastest market growth during the forecast period, owing to constantly expanding healthcare infrastructure, economic development, are projected to drive the growth of the novel vaccine delivery systems market in emerging countries in Asia-Pacific. In addition, Asia-Pacific is the most populous region across the globe. Increase in population is further anticipated to proliferate increased consumption of vaccines, which ultimately drives the novel vaccine delivery systems market growth. Moreover, growing immunization programs and their increasing coverage also boost the market growth of novel vaccine delivery system market. According to National Health System, the Government of India's Universal Immunization Program provides immunization against seven vaccine-preventable diseases: Diphtheria, Pertussis, Tetanus, Polio, Measles, severe form of Childhood Tuberculosis, Hepatitis B, Hiaemophilus influenza type b (Hib) and Diarrhea. In addition, according to UNICEF India 2020, over 9 million immunization sessions are held across India every year toward full immunization coverage. The Program introduced new vaccines, including the Pneumococcal Conjugate Vaccine (PCV) and Rotavirus Vaccine (RVV). 

The key market players profiled in the report include Altaris Capital Partners, LLC (Kindeva Drug Delivery), Becton, Dickinson, and Company, Carl Zeiss Foundation (Schott AG), Gerresheimer AG, Gurnet Point Capital (Corium International Inc.), Inovio Pharmaceuticals, Inc. (Bioject Medical Technologies), PharmaJet, Inc., Retractable Technologies, Inc., Terumo Corporation, and VAXXAS Pty Ltd.

Novel Vaccine Delivery Systems Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America is expected to experience growth at the highest rate, registering a CAGR of 9.8 % during the forecast period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global novel vaccine delivery systems market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the novel vaccine delivery systems market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing novel vaccine delivery systems market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of novel vaccine delivery systems used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the novel vaccine delivery systems market.

Key Market Segments

By Delivery Mode

  • Intradermal 
  • Subcutaneous
  • Intramuscular 
  • Other

By Device

  • Syringe
    • Conventional Syringe
    • Smart Syringe
      • Active Safety Syringes
      • Passive Safety Syringes
      • Auto Disable Syringes
  • Needle free injection System
    • Spring-based Injector Systems
    • Gas Propelled/Air Forced Injector Systems
    • Others
  • Others 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Growing immunization programs & their increasing coverage
3.5.1.2.Increasing government support and investment
3.5.1.3.Development of novel vaccines

3.5.2.Restraints

3.5.2.1.High cost and unaffordability of safety syringes
3.5.2.2.Alternative modes of drug delivery

3.5.3.Opportunities

3.5.3.1.Rise in need for safety syringes in emerging economies
3.5.3.2.FDA approval to COVID 19 Vaccine

3.5.4.Impact analysis

3.6.Covid-19 Impact analysis on novel vaccine delivery system market

CHAPTER 4:NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE

4.1.Overview

4.1.1.Market size and forecast

4.2.Intradermal

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Subcutaneous

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Intramuscular

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

CHAPTER 5:NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE

5.1.Overview

5.1.1.Market size and forecast

5.2.Syringe

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.2.4.Market size and forecast, by type

5.2.5.General Syringe
5.2.6.Smart Syringe

5.2.6.1.Market size and forecast
5.2.6.2.Smart Syringe, By type
5.2.6.3.smart syringe, market size and forecast, by type

5.2.6.3.1.Auto disable syringes, market size and forecast
5.2.6.3.2.Active safety syringes, market size and forecast
5.2.6.3.3.Passive safety syringes, market size and forecast

5.3.Needle-free Injection System

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast
5.3.3.Market analysis, by country
5.3.4.Market size and forecast, by type
5.3.5.Spring-based Injector Systems

5.3.5.1.Market size and forecast

5.3.6.Gas Propelled/Air Forced Injector Systems

5.3.6.1.Market size and forecast

5.3.7.Others

5.3.7.1.Market size and forecast

5.4.Others

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast
5.4.3.Market analysis, by country

CHAPTER 6:NOVEL VACCINE DELIVERY SYSTEM, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. Novel vaccine delivery system, by delivery mode
6.2.2.1.2.U.S. Novel vaccine delivery system, by device

6.2.2.2.Canada

6.2.2.2.1.Canada Novel vaccine delivery system, by delivery mode
6.2.2.2.2.Canada Novel vaccine delivery system, by device

6.2.2.3.Mexico

6.2.2.3.1.Mexico Novel vaccine delivery system, by delivery mode
6.2.2.3.2.Mexico Novel vaccine delivery system, by device

6.2.3.North America market size and forecast, by delivery mode
6.2.4.North America market size and forecast, by device

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country

6.3.2.1.Germany

6.3.2.1.1.Germany Novel vaccine delivery system, by delivery mode
6.3.2.1.2.Germany Novel vaccine delivery system, by device

6.3.2.2.France

6.3.2.2.1.France Novel vaccine delivery system, by delivery mode
6.3.2.2.2.France Novel vaccine delivery system, by device

6.3.2.3.UK

6.3.2.3.1.UK Novel vaccine delivery system, by delivery mode
6.3.2.3.2.UK Novel vaccine delivery system, by device

6.3.2.4.Italy

6.3.2.4.1.Italy Novel vaccine delivery system, by delivery mode
6.3.2.4.2.Italy Novel vaccine delivery system, by device

6.3.2.5.Spain

6.3.2.5.1.Spain Novel vaccine delivery system, by delivery mode
6.3.2.5.2.Spain Novel vaccine delivery system, by device

6.3.2.6.Rest of Europe

6.3.2.6.1.Rest of Europe Novel vaccine delivery system, by delivery mode
6.3.2.6.2.Rest of Europe Novel vaccine delivery system, by device

6.3.3.Europe market size and forecast, by delivery mode
6.3.4.Europe market size and forecast, by device

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country

6.4.2.1.Japan

6.4.2.1.1.Japan Novel vaccine delivery system, by delivery mode
6.4.2.1.2.Japan Novel vaccine delivery system, by device

6.4.2.2.China

6.4.2.2.1.China Novel vaccine delivery system, by delivery mode
6.4.2.2.2.China Novel vaccine delivery system, by device

6.4.2.3.Australia

6.4.2.3.1.Australia Novel vaccine delivery system, by delivery mode
6.4.2.3.2.Australia Novel vaccine delivery system, by device

6.4.2.4.India

6.4.2.4.1.India Novel vaccine delivery system, by delivery mode
6.4.2.4.2.India Novel vaccine delivery system, by device

6.4.2.5.South Korea

6.4.2.5.1.South Korea Novel vaccine delivery system, by delivery mode
6.4.2.5.2.South Korea Novel vaccine delivery system, by device

6.4.2.6.Rest of Asia-Pacific

6.4.2.6.1.Rest of Asia-Pacific Novel vaccine delivery system, by delivery mode
6.4.2.6.2.Rest of Asia-Pacific Novel vaccine delivery system, by device

6.4.3.Asia-Pacific market size and forecast, by delivery mode
6.4.4.Asia-Pacific market size and forecast, by device

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil Novel vaccine delivery system, by delivery mode
6.5.2.1.2.Brazil Novel vaccine delivery system, by device

6.5.2.2.Saudi Arabia

6.5.2.2.1.Saudi Arabia Novel vaccine delivery system, by delivery mode
6.5.2.2.2.Saudi Arabia Novel vaccine delivery system, by device

6.5.2.3.South Africa

6.5.2.3.1.South Africa Novel vaccine delivery system, by delivery mode
6.5.2.3.2.South Africa Novel vaccine delivery system, by device

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA Novel vaccine delivery system, by delivery mode
6.5.2.4.2.Rest of LAMEA Novel vaccine delivery system, by device

6.5.3.LAMEA market size and forecast, by delivery mode
6.5.4.LAMEA market size and forecast, by device

CHAPTER 7:COMPANY PROFILES

7.1.CAPITAL PARTNERS, LLC (KINDEVA DRUG DELIVERY)

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.BECTON, DICKINSON, AND COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.

7.3.CARL ZEISS FOUNDATION (SCHOTT AG)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.GERRESHEIMER AG

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.GURNET POINT CAPITAL (CORIUM INTERNATIONAL INC.)

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.

7.6.INOVIO PHARMACEUTICALS, INC. (BIOJECT MEDICAL TECHNOLOGIES)

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.PHARMAJET, INC.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.RETRACTABLE TECHNOLOGIES, INC.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.TERUMO CORPORATION

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.VAXXAS PTY LTD

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE, 2020-2030($MILLION)
TABLE 02.INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 03.INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 04.SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 05.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 06.GLOBAL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030($MILLION)
TABLE 07.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY REGION, 2020-2030($MILLION)
TABLE 08.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY TYPE, 2020–2030, ($MILLION)
TABLE 09.NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 10.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR NEEDLE FREE INJECTION SYSTEM, BY TYPE, 2020–2030, ($MILLION)
TABLE 11.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 12.NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
TABLE 13.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 14.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 15.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 16.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 17.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 18.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 19.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 20.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 21.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 22.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 23.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 24.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 25.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 26.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 27.UK NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 28.UK NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 29.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 30.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 31.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 32.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 33.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 34.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 35.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 36.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 37.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 38.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 39.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 40.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 41.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 42.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 43.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 44.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 45.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 46.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 47.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 48.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 49.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 50.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 51.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 52.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
TABLE 53.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 54.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 55.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 56.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 57.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 58.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 59.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 60.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 61.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
TABLE 62.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
TABLE 63.ALTARIS: COMPANY SNAPSHOT
TABLE 64.ALTARIS: PRODUCT PORTFOLIO
TABLE 65.BD: COMPANY SNAPSHOT
TABLE 66.BD: OPERATING SEGMENTS
TABLE 67.BD: PRODUCT PORTFOLIO
TABLE 68.BD: NET SALES, 2018–2020 ($MILLION)
TABLE 69.BD: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 70.BD: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 71.CARL ZEISS: COMPANY SNAPSHOT
TABLE 72.CARL ZEISS: PRODUCT PORTFOLIO
TABLE 73.GERRESHEIMER: COMPANY SNAPSHOT
TABLE 74.GERRESHEIMER: OPERATING SEGMENTS
TABLE 75.GERRESHEIMER: PRODUCT PORTFOLIO
TABLE 76.GERRESHEIMER: NET SALES, 2018–2020 ($MILLION)
TABLE 77.GERRESHEIMER: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 78.GERRESHEIMER: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 79.GURNET POINT: COMPANY SNAPSHOT
TABLE 80.GURNET POINT: PRODUCT PORTFOLIO
TABLE 81.INOVIO: COMPANY SNAPSHOT
TABLE 82.INOVIO: PRODUCT PORTFOLIO
TABLE 83.INOVIO: NET SALES, 2018–2020 ($MILLION)
TABLE 84.PHARMAJET: COMPANY SNAPSHOT
TABLE 85.PHARMAJET: OPERATING SEGMENT
TABLE 86.PHARMAJET: PRODUCT PORTFOLIO
TABLE 87.RETRACTABLE TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 88.RETRACTABLE: PRODUCT PORTFOLIO
TABLE 89.RETRACTABLE TECHNOLOGIES: NET SALES, 2018–2020 ($MILLION)
TABLE 90.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 91.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 92.TERUMO: COMPANY SNAPSHOT
TABLE 93.TERUMO: OPERATING SEGMENTS
TABLE 94.TERUMO: PRODUCT PORTFOLIO
TABLE 95.TERUMO: NET SALES, 2018–2020 ($MILLION)
TABLE 96.TERUMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
TABLE 97.TERUMO: REVENUE SHARE, BY REGION, 2020 (%)
TABLE 98.VAXXAS: COMPANY SNAPSHOT
TABLE 99.VAXXAS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.HIGH INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF OTHER NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13.CONVENTIONAL SYRINGE MARKET, 2020–2030, ($MILLION)
FIGURE 14.SMART SYRINGE MARKET, 2020–2030, ($MILLION)
FIGURE 15.GLOBAL SMART SYRINGE MARKET, BY TYPE, 2020–2030 ($MILLION)
FIGURE 16.GLOBAL SMART SYRINGE MARKET FOR ACTIVE SAFETY SYRINGES, BY TYPE 2020–2030 ($MILLION)
FIGURE 17.GLOBAL SMART SYRINGE MARKET FOR PASSIVE SAFETY SYRINGES, BY TYPE, 2020–2030 ($MILLION)
FIGURE 18.GLOBAL SMART SYRINGE MARKET FOR AUTO DISABLE SYRINGES, BY TYPE 2020–2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.SPRING-BASED INJECTOR SYSTEMS MARKET, 2020–2030, ($MILLION)
FIGURE 21.GAS PROPELLED/AIR FORCED INJECTOR SYSTEMS MARKET, 2020–2030, ($MILLION)
FIGURE 22.OTHERS MARKET, 2020–2030, ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION) 

 
 

Vaccine is a suspension containing weakened or destroyed microbes or toxins, as well as antibodies and lymphocytes that are given to prevent sickness. Vaccines stimulate the immune system to combat certain pathogens. Formulations, technologies, methods, and systems for transferring an active pharmaceutical component throughout the body as required in order to safely achieve its therapeutic effect are all included in novel vaccine delivery.

Growing immunization programs & their increasing coverage, increasing government support and investment, development of novel vaccines, are expected to drive the growth of the novel vaccine delivery system. Furthermore, rise in need for safety syringes in emerging economies and FDA approval to COVID 19 Vaccine also create a lucrative opportunity for market growth. However, high cost and unaffordability of safety syringes, alternative modes of drug delivery are expected to hinder the growth of the market. 

North America is expected to remain dominant during the forecast period. The rising incidence of a number of chronic illnesses and disorders, such as polio, measles, and influenza, is driving demand for vaccination and contributes toward growth of the novel vaccine delivery system in this region. Moreover, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period. The market growth in this region is attributable to the large patient pool, increase in healthcare awareness, rise in healthcare expenditure, growth in disposable income, and rise in government spending.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285,
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Novel Vaccine Delivery Systems market is $5,029.6 million in 2020.

A. The forcast period for Novel Vaccine Delivery Systems market is 2021 to 2030

A. The market value of Novel Vaccine Delivery Systems market in 2021 is $5,738.8 million.

A. The base year is 2020 in Novel Vaccine Delivery Systems market

A. Top companies such as 3M Company, Becton Dickinson & Company, Bioject Medical Technologies, Inc. (Inovio Pharmaceutical Inc.), Corium International, Inc., Gerresheimer AG, Medtronic plc., PharmaJet, SCHOTT AG, Retractable Technologies, Inc., and Vaxxas. held a high market position in 2020.

A. Syringe segment is the most influencing segment owing to cost effectiveness of syringes and they are used in routine immunization and mass vaccination programs. Moreover, syringes are the most common device used in vaccine delivery.

A. Growing immunization programs & their increasing coverage, increasing government support for various immunization programs and investment for R & D to develop new vaccines drive the growth of market.In addition, rise in need for safety syringes in emerging economies and FDA approval to COVID-19 Vaccine create lucrative opportunities for the novel vaccine delivery system.

A. Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing tolarge patient pool, increase in healthcare awareness, rise in healthcare expenditure, growth in disposable income, and rise in government spending.

A. The term "novel vaccine delivery" refers to formulations, technologies, procedures, and systems that are used to safely deliver an active medicinal component into the body.

A. Novel Vaccine Delivery Systems products are used to safely deliver an active medicinal component into the body.

Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Novel Vaccine Delivery Systems Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers